This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 The latest oncology news, trials, and practice-changing data — all in one place. 🔴 **LUNG:** DeLLphi-305 shows an OS benefit with **tarlatamab + durvalumab** in extensive-stage SCLC. Plus, new insights into **lazertinib** resistance/ctDNA clearance and **osimertinib** in uncommon EGFR mutations. 🟠 **GI:** Promising Phase 1 data explore **L-glutamine + gemcitabine/nab-paclitaxel** in advanced pancreatic cancer. 🔵 **GU:** New data on perioperative treatment strategies in **high-risk prostate cancer** and fracture risk with **abiraterone**. 🟣 **BREAST:** New insights into pCR with neoadjuvant THP in **HER2+ disease** and biomarkers in **stage I TNBC**. 🌍 **PLUS:** Meet **AcuVox** — a free platform helping oncology professionals track the trials, treatments, and topics generating the most attention at major cancer congresses. 👉 **Stay informed. Stay ahead. Read this week’s OncoAlert Newsletter.** #OncoAlert# #Oncology# #CancerResearch# #LungCancer# #BreastCancer# #ProstateCancer# #PancreaticCancer# @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

The OncoAlert Newsletter June 25- July 1, ,2026 REGISTER TO GET IT👉 or 🔥 Highlights include: 🔹 Industry Update: 🇪🇺 EU approval of trastuzumab deruxtecan as the first tumour-agnostic HER2-directed ADC for previously treated HER2-positive solid tumors — expanding the impact of biomarker-driven oncology. #ADC# #PrecisionOncology# #HER2# 🔹 Lung Cancer: 🫁 TP53 gain-of-function mutations linked to early osimertinib resistance in EGFR-mutant NSCLC 🫁 Identifying patients at risk for early failure with dual immunotherapy in metastatic NSCLC 🔹 GU Cancers: 🧬 9+ year follow-up confirms durable survival benefit of nivolumab + ipilimumab in advanced RCC 🧬 PSMA PET/CT-guided MDT associated with improved outcomes in oligometastatic CRPC 🔹 Breast Cancer: 🎗️ iSBRT + immunotherapy strategies in ER+/HER2− disease 🎗️ Pregnancy-associated breast cancer outcomes and the role of tumor biology 🔹 GI Cancers: 🎯 New ESTRO recommendations for rectal cancer reirradiation 🎯 Real-world data on adjuvant chemotherapy in biliary tract cancers 🔹 Cancer & Innovation: 🤖 AI decision support in hematologic malignancies 🤖 Machine learning models for cervical cancer risk stratification 🧬 The evolving role of intratumoral therapies in melanoma 📚 Stay updated with the latest evidence shaping clinical practice. @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia